FDA Rejects New Drug Application for Synthetic Hypericin
OncLive,
Christopher J. Schaber, PhD The FDA has issued a refusal to file letter for a new drug application (NDA) for HyBryte, Soligenix’s…
Christopher J. Schaber, PhD The FDA has issued a refusal to file letter for a new drug application (NDA) for HyBryte, Soligenix’s…
Although cutaneous T-cell lymphoma, a group of non-Hodgkin T-cell lymphomas, remains a rare disease, incidence has increased…